Compass Therapeutics (CMPX) Total Current Liabilities (2023 - 2025)
Historic Total Current Liabilities for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $12.4 million.
- Compass Therapeutics' Total Current Liabilities rose 17999.1% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 17999.1%. This contributed to the annual value of $8.9 million for FY2024, which is 1375.46% up from last year.
- Compass Therapeutics' Total Current Liabilities amounted to $12.4 million in Q3 2025, which was up 17999.1% from $13.9 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Total Current Liabilities registered a high of $14.9 million during Q1 2025, and its lowest value of $3.9 million during Q1 2024.
- Over the past 3 years, Compass Therapeutics' median Total Current Liabilities value was $9.5 million (recorded in 2024), while the average stood at $9.6 million.
- As far as peak fluctuations go, Compass Therapeutics' Total Current Liabilities plummeted by 6521.0% in 2024, and later soared by 28273.82% in 2025.
- Compass Therapeutics' Total Current Liabilities (Quarter) stood at $7.8 million in 2023, then rose by 13.75% to $8.9 million in 2024, then soared by 39.87% to $12.4 million in 2025.
- Its Total Current Liabilities was $12.4 million in Q3 2025, compared to $13.9 million in Q2 2025 and $14.9 million in Q1 2025.